Table 2 Underlying risk and comorbid condition
|  | Overall, N = 1341 | STEMI, N = 771 | NSTEMI, N = 571 | p-value2 |
|---|---|---|---|---|
HTN, n (%) | 101 (75.4) | 56 (72.7) | 45 (78.9) | 0.41 |
DM, n (%) | 58 (43.2) | 33 (42.9) | 19 (33.3) | 0.26 |
Both DM and HTN n (%) | 44 (32.8) | 28 (36.4) | 16 (28.1) | 0.31 |
HBA1C, Median (IQR) | 9.0 (6.9–10.8) | 9.0 (6.9–10.6) | 8.0 (7.0–10.5) | 0.95 |
Categories of HBA1C n (%) < 6.5% 6.5-7% > 7% | 7(13.7) 11(21.6) 33(64.7) | 5(15.6) 6(18.8) 21(65.6) | 2(10.5) 5(26.3) 12(63.2) | 0.83 |
Therapy among DM, n (%) Non- Pharmacotherapy Oral Insulin Oral and insulin | 5(8.6) 31(53.4) 14(24.1) 8(13.8) | 5(12.8) 21(53.8) 7(17.9) 6(15.4) | 0(0) 10(52.6) 7(36.8) 2(10.5) | 0.24 |
Smoking | 69 (51.5) | 43(55.8) | 26(45.6) | 0.90 |
On Cholesterol lowering medication prior presentation, n (%) | 68 (50.7) | 33(42.9) | 35(61.4) | 0.13 |
Previous MI, n (%) | 16 [11] | 8(10.4) | 8 [14] | 0.52 |
Family history of Premature ASCVD, n (%) | 72(53.7) | 43(55.8) | 29(50.8) | 0.33 |
Other Comorbid Conditions, n (%) Hypothyroidism Hyperthyroidism CKD and ESRD HIV Connective tissue disease Asthma Polycythemia | 14(10.4) 3(2.2) 8(5.9) 3(2.2) 12(8.9) 3(2.2) 6(4.5) | 6(7.8%) 3(3.9) 2(2.6) 3(3.9) 5(6.5) 1(1.3) 5(6.5) | 8(14.1) 0(0.0) 6(10.5) 0(0) 7(12.3) 2(3.6) 1(1.8) | 0.33 |